Many cancers are much more curable if detected early. However, the current suite of detection methods are slow, expensive and can’t detect a problem until it is advanced. Dr. Steven Quake of the Chan-Zukerberg Biohub is working with a group to perfect the liquid biopsy. Using just a patient’s blood, the test strive to identify cell-free RNA and /or DNA that often is shed into the bloodstream from solid tumors. Detection of such molecules may help diagnosticians identify cellular transformation events before symptoms ever are experienced. The relatively inexpensive and non-invasive test will likely be a central part of every annual physical, as it can detect problems long before they become problematic.# COLABRATalking Biotech is brought to you by Colabra – an R&D platform that brings your lab’s world-changing research together in one shared space. Learn more at https://www.colabra.app/# TALKING BIOTECHTwitter: https://twitter.com/talkingbiotechWebsite: https://www.colabra.app/podcasts/talking-biotech/Instagram: https://www.instagram.com/colabrahqThe Talking Biotech podcast is distinct from Dr. Kevin Folta's teaching and research roles at the University of Florida. The views expressed on the show are those of Dr. Folta and his guests, and do not reflect the opinions of the university or Colabra.